Literature DB >> 15365064

Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma.

Jonathan H Lee1, Richard Essner, Hitoe Torisu-Itakura, Leslie Wanek, Hejing Wang, Donald L Morton.   

Abstract

PURPOSE: Approximately 20% of sentinel node (SN) positive melanoma patients have additional non-SN (NSN) metastasis. The rationale for this study was to identify the factors associated with additional nodal disease, as a method to determine which patients may most benefit from completion lymph node dissection (CLND). PATIENTS AND METHODS: During 1990 to 2002, 1,599 patients have undergone SN biopsy at our institute. 19.5% underwent CLND for tumor-positive SN. One hundred ninety-one of these patients had clinicopathologic information available for review. Univariate analyses used chi2 test, Wilcoxson rank sum test, and chi2 test for trend. Multivariate analyses used logistic regression and Wald test.
RESULTS: Forty-six (24%) patients had tumor-positive NSN. Univariate analyses showed that primary thickness (Breslow and Clark), primary site, SN tumor size, and number of tumor-positive SNs were significantly associated with tumor-positive NSN. Multivariate analysis (167 patients), confirmed that Breslow and SN tumor size were independently predictive. Sex, histology, ulceration, mitotic index, and SN basin location were not predictive. Risk stratification by the number of prognostic factors present (Breslow > or = 3 mm and SN tumor size > or = 2 mm) showed that probability of finding tumor-positive NSN was 12.3% in the low-risk group (0 factors), 30.9% in the intermediate-risk group (1 factor), and 41.9% in the high-risk group (2 factors).
CONCLUSION: Thicker primary and larger SN tumor size are factors that correlate best with tumor-positive NSN. Although none of these factors are absolutely predictive of residual nodal disease, these factors must be strongly considered if the SN contains metastasis, as they provide enhanced risk assessment for NSN tumor-positivity.

Entities:  

Mesh:

Year:  2004        PMID: 15365064     DOI: 10.1200/JCO.2004.01.012

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  25 in total

1.  Gender-related differences in outcome for melanoma patients.

Authors:  Charles R Scoggins; Merrick I Ross; Douglas S Reintgen; R Dirk Noyes; James S Goydos; Peter D Beitsch; Marshall M Urist; Stephan Ariyan; Jeffrey J Sussman; Michael J Edwards; Anees B Chagpar; Robert C G Martin; Arnold J Stromberg; Lee Hagendoorn; Kelly M McMasters
Journal:  Ann Surg       Date:  2006-05       Impact factor: 12.969

2.  Enhanced postoperative lymphatic staging of malignant melanoma by endoscopically assisted iliacoinguinal dissection.

Authors:  I M Ising; A Bembenek; R Gutzmer; F Köckerling; K T Moesta
Journal:  Langenbecks Arch Surg       Date:  2011-12-24       Impact factor: 3.445

Review 3.  Surgery and sentinel lymph node biopsy.

Authors:  Mark B Faries; Donald L Morton
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

Review 4.  The role of radiation therapy in the management of cutaneous melanoma.

Authors:  Charlene E Kan; David B Mansur
Journal:  Melanoma Manag       Date:  2016-02-24

Review 5.  Surgical treatment of melanoma patients with early sentinel node involvement.

Authors:  Rosemarie E Hardin; Julie R Lange
Journal:  Curr Treat Options Oncol       Date:  2012-09

6.  Is the non-sentinel lymph node compartment the next site for melanoma progression from the sentinel lymph node compartment in the regional nodal basin?

Authors:  Andrei Rios-Cantu; Ying Lu; Victor Melendez-Elizondo; Michael Chen; Alejandra Gutierrez-Range; Niloofar Fadaki; Suresh Thummala; Carla West-Coffee; James Cleaver; Mohammed Kashani-Sabet; Stanley P L Leong
Journal:  Clin Exp Metastasis       Date:  2017-07-11       Impact factor: 5.150

7.  Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial.

Authors:  Donald L Morton; Alistair J Cochran; John F Thompson; Robert Elashoff; Richard Essner; Edwin C Glass; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; He-jing Wang
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

8.  Impact of Completion Lymph Node Dissection on Patients with Positive Sentinel Lymph Node Biopsy in Melanoma.

Authors:  David Y Lee; Briana J Lau; Kelly T Huynh; Devin C Flaherty; Ji-Hey Lee; Stacey L Stern; Steve J O'Day; Leland J Foshag; Mark B Faries
Journal:  J Am Coll Surg       Date:  2016-01-29       Impact factor: 6.113

9.  Melanoma controversies: clinical significance of nodal micrometastases and the future of melanoma vaccines.

Authors:  Kelly M McMasters
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

10.  Survival and the sentinel lymph node in melanoma.

Authors:  Mark Faries
Journal:  Ann Surg Oncol       Date:  2010-01       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.